Compare Garmin Ltd. (GRMN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Recursion Pharmaceuticals Inc — how do they compare? Garmin Ltd. trades at $268.6 (market cap $51.77B), while Recursion Pharmaceuticals Inc trades at $4.26 (market cap $2.14B). The key difference: Garmin Ltd. is far larger — about 24.2× Recursion Pharmaceuticals Inc's market cap, and Garmin Ltd. pays a 1.56% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GRMN | RXRX | |
|---|---|---|
Market Cap | $51.77B | $2.14B |
Volume | 961,398 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $313.16 | $6.79 |
52-Week Low | $187.10 | $2.84 |
Typical Hold Time | 83 Days | 22 Days |
Enterprise Value | $49.28B | $1.66B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.16, down 1.09% on the day, with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $4.9B in 2022 to $7.25B in 2025, and robust profitability margins. Recent news highlights product innovation and industry awards, reinforcing its market position.
The outlook is supported by solid financial health and analyst consensus pointing to upside, but risks include competitive pressures and market volatility. The stock presents a growth opportunity driven by execution, though investor caution is warranted near-term given technical weakness and macroeconomic uncertainties.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
